| scholarly article | Q13442814 |
| P50 | author | Mohammad T. Hedayati | Q37607217 |
| Seyedmojtaba Seyedmousavi | Q40062294 | ||
| Willem Melchers | Q56859383 | ||
| Mojtaba Taghizadeh Armaki | Q59138014 | ||
| Paul E. Verweij | Q70514014 | ||
| P2093 | author name string | Saham Ansari | |
| Jan Zoll | |||
| Henrich A van der Lee | |||
| Haleh Rafati | |||
| Sasan Saber | |||
| Saeed Mahdavi Omran | |||
| P2860 | cites work | Invasive aspergillosis in critically ill patients without malignancy | Q80269940 |
| Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America | Q28263689 | ||
| Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus | Q28481341 | ||
| High resolution of human evolutionary trees with polymorphic microsatellites | Q29614665 | ||
| Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism | Q30853962 | ||
| Influences of climate on aflatoxin producing fungi and aflatoxin contamination | Q31129997 | ||
| High resolution genotyping of clinical Aspergillus flavus isolates from India using microsatellites | Q33802593 | ||
| Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates | Q34041500 | ||
| Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis. | Q34077069 | ||
| Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America | Q34532546 | ||
| Molecular identification and antifungal susceptibility profile of Aspergillus flavus isolates recovered from clinical specimens in Kuwait | Q34621506 | ||
| Aspergillosis. Pathogenesis, clinical manifestations, and therapy | Q35038459 | ||
| In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network | Q35139558 | ||
| Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature | Q35666591 | ||
| Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections | Q35666612 | ||
| Characterization of a novel gene for strain typing reveals substructuring of Aspergillus fumigatus across North America | Q35947150 | ||
| Quantitative Analysis of Single-Nucleotide Polymorphism for Rapid Detection of TR34/L98H- and TR46/Y121F/T289A-Positive Aspergillus fumigatus Isolates Obtained from Patients in Iran from 2010 to 2014. | Q36439193 | ||
| Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates. | Q36671086 | ||
| Aspergillus flavus: human pathogen, allergen and mycotoxin producer. | Q36831943 | ||
| In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus. | Q36993501 | ||
| Sequence-based identification of Aspergillus, fusarium, and mucorales species in the clinical mycology laboratory: where are we and where should we go from here? | Q37156876 | ||
| Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus | Q37226618 | ||
| Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods | Q37374949 | ||
| Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis | Q37538782 | ||
| A review molecular typing methods for Aspergillus flavus isolates | Q37849192 | ||
| Susceptibility testing in Aspergillus species complex | Q38174191 | ||
| The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside. | Q38234496 | ||
| Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). | Q38726054 | ||
| Systemic Antifungal Agents: Current Status and Projected Future Developments. | Q38796140 | ||
| Therapeutic outcome in invasive aspergillosis | Q38970340 | ||
| Azole resistance surveillance in Aspergillus fumigatus: beneficial or biased? | Q39520292 | ||
| In vitro antifungal susceptibility of clinically relevant species belonging to Aspergillus section Flavi. | Q39767031 | ||
| A Novel Y319H Substitution in CYP51C Associated with Azole Resistance in Aspergillus flavus. | Q40653596 | ||
| EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents | Q40802185 | ||
| Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles | Q41370116 | ||
| Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method. | Q41771784 | ||
| Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles | Q42018512 | ||
| Microsatellite typing of Aspergillus flavus from clinical and environmental avian isolates | Q42059395 | ||
| Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). | Q42116260 | ||
| Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis. | Q42257843 | ||
| Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document) | Q42428186 | ||
| In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method | Q42576501 | ||
| In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method | Q42731754 | ||
| In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies. | Q44146174 | ||
| An opportunistic human pathogen on the fly: strains of Aspergillus flavus vary in virulence in Drosophila melanogaster | Q44622508 | ||
| EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole | Q45152541 | ||
| EUCAST technical note on voriconazole and Aspergillus spp. | Q45886335 | ||
| Comparison of the EUCAST-AFST broth dilution method with the CLSI reference broth dilution method (M38-A) for susceptibility testing of posaconazole and voriconazole against Aspergillus spp. | Q46444751 | ||
| Antifungal susceptibility of the aspergillus species by Etest and CLSI reference methods. | Q50934170 | ||
| In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs. | Q51037587 | ||
| EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia–forming moulds | Q56837279 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | genetic diversity | Q585259 |
| Aspergillus flavus | Q137096 | ||
| P577 | publication date | 2017-04-24 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Genetic Diversity and In Vitro Antifungal Susceptibility of 200 Clinical and Environmental Aspergillus flavus Isolates | |
| P478 | volume | 61 |
Search more.